Recruiting Pneumonia Studies in Chicago
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thr...
About Pneumonia Clinical Trials in Chicago
Pneumonia is an infection that inflames the air sacs in one or both lungs, which may fill with fluid or pus. It can range from mild to life-threatening. Treatment depends on the cause and severity, including antibiotics, antivirals, and supportive care.
There are currently 2 pneumonia clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 24,000 participants. Research is being sponsored by UMC Utrecht, University of Manitoba. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pneumonia Clinical Trials in Chicago — FAQ
Are there pneumonia clinical trials in Chicago?
Yes, there are 2 pneumonia clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chicago?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.
Are clinical trials in Chicago free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.
What pneumonia treatments are being tested?
The 2 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for pneumonia.
Data updated March 2, 2026 from ClinicalTrials.gov